Aqtual, Inc. utilizes a proprietary cell-free DNA platform to develop highly accurate blood tests for chronic diseases and oncology, focusing on biomarkers that guide therapy management. The company addresses the challenge of ineffective treatment responses in chronic inflammatory conditions, such as rheumatoid arthritis, by providing clinically actionable insights from a single blood draw.
Funding
$31.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MRYGFounders
Product
Problem
Patients with chronic inflammatory conditions like rheumatoid arthritis often experience ineffective treatment responses, requiring them to switch therapies after extended periods on expensive medications. Current diagnostic methods lack the ability to predict treatment response, leading to delays in effective therapy and increased healthcare costs.
Solution
Aqtual, Inc. has developed a cell-free DNA platform to create blood tests that provide clinically actionable insights for managing chronic diseases and oncology. The platform analyzes circulating chromatin, previously inaccessible through standard lab methods, to identify tissue-, disease-, and drug-specific targets. By measuring epigenetics, gene regulation, and transcriptomics from a single blood draw, Aqtual's technology aims to predict treatment response and guide therapy management, initially focusing on rheumatoid arthritis. The company's approach involves capturing and quantifying cell-free DNA, followed by signal processing and validation against a catalog of clinically actionable signatures.
Target Audience
The primary target audience includes rheumatologists and other physicians treating chronic inflammatory conditions, as well as pharmaceutical companies developing and marketing therapies for these diseases.
Features
- Proprietary cell-free DNA capture method for analyzing circulating chromatin
- Measures epigenetics, gene regulation, and transcriptomics from a single blood draw
- Identifies tissue-, disease-, and drug-specific targets in inflammatory conditions and oncology
- Validated catalog of clinically actionable signatures
- Signal processing techniques to quantify biomarkers associated with treatment response
- Development of classifiers to predict treatment response in rheumatoid arthritis patients